Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Prepared Patient: Managing Mental And Medical Illness
In her 1984 boot camp graduation photo, Adrienne Fitts is smiling. Her hair is neatly groomed, her Navy cap and dress whites are spotless and she is regulation fit and trim.

Inovio Biomedical, National Microbiology Laboratory, And University Of Pennsylvania To Evaluate Candidate DNA Vaccines Against "Swine" Influenza A
Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today it has established a new collaboration with the National Microbiology Laboratory of the Public Health Agency of Canada and the University of Pennsylvania to further evaluate Inovio DNA vaccine candidates against swine influenza A (H1N1) virus. As a part of its universal influenza vaccine program, Inovio has designed and manufactured consensus DNA vaccines for H1N1 influenza strains. These consensus vaccines, delivered using Inovio"s proprietary electroporation technology, have the potential to provide protection against a broad scope of existing as well as currently unknown, unmatched influenza strains that could emerge -- one of the perpetual challenges in trying to protect against influenza. The purpose of this collaboration is to test these vaccine candidates against pandemic and seasonal influenza strains in animal models and will include testing against a recently identified swine H1N1 strain.
News of the day
Biolex Therapeutics Announces Completion Of Enrollment In SELECT-2 Phase 2b Trial Of Locteron(R) In Chronic Hepatitis C
Biolex Therapeutics, Inc. announced that it has completed patient enrollment in the SELECT-2 Phase 2b trial of its lead product candidate Locteron® for the treatment of chronic hepatitis C. Locteron, controlled-release interferon alpha 2b, is designed to improve patient care by providing a more convenient once-every-two week dosing schedule and by reducing the side effects, including flu-like symptoms, associated with pegylated interferons, the current standard of care.
Sexual Health

Innovative Medicines Initiative Provides 246 Million Euros To Support Public-private Research Cooperation For The Faster Development Of Innovative Med

Today, fifteen new research projects aimed at bringing innovative medicines to market faster have been selected to receive 246 million Euros from the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), of which the Irish Pharmaceutical Healthcare Association (IPHA) is a member. The projects will foster understanding of health issues such as diabetes, pain, severe asthma and psychiatric disorders while increasing medicine safety. They will also help improve the training of researchers and clinicians involved in medicines development. The projects were chosen following the first call for proposals launched within the Innovative Medicines Initiative (IMI), a public-private partnership - so called Joint Technology Initiative - between the European Commission and the pharmaceutical industry. With this selection, IMI has reached a key milestone. This initiative marks the first time that pharmaceutical competitors are pooling their res, together with research organisations, patient groups and other stakeholders in large consortia, in order to develop generic, pre-competitive knowledge. The Commission"s contribution of €110 million is backed up with €136 million provided in-kind from the pharmaceutical industry. The successful projects will now enter into the final negotiation phase. "I"m happy to see that this unique public-private partnership that was launched as a new instrument for research two years ago is bearing fruit. In times of crisis, such a model of cooperation is proving particularly well suited to answering both EU public health and economic needs," said Janez Potonik, the EU Commissioner for Science and Research. Arthur Higgins, CEO of Bayer Healthcare and EFPIA President, stated, "I am delighted to see that this pioneering model of collaboration between industry and the Commission has been taken up so positively all across Europe. The IMI will set new standards in data sharing and knowledge exchange." Better medicines reaching patients faster The projects selected will address the main causes of delay, or "bottlenecks", in the pharmaceutical research and development (R&D) process. The overall objective is to encourage the more rapid discovery and development of better medicines for patients while improving the competitiveness of the European pharmaceutical industry. The projects will help to increase predicted safety and efficacy of medicines, enhance data exchange between researchers and improve education and training in the sector. The selection process: a substantial interest from stakeholders Around 150 applications were received. The best consortia, consisting of research organisations, Small and Medium Enterprises (SMEs), academia, patient organisations, and regulatory bodies, were selected in the first peer review to form joint project teams with the corresponding EFPIA consortia. On the basis of stringent scientific criteria and their potential impact on the identified "bottlenecks", 15 projects from these teams have been selected. European funding to boost the R&D capabilities of the public sector and SMEs Pharmaceutical companies within EFPIA will fully fund their own participation by providing R&D res including staff, laboratory facilities, materials and clinical research. European Community"s funds will be allocated exclusively to other participants (public sector, SMEs, patient groups, academics). Further steps Contract negotiations for the 15 projects should be finished by November 2009. A second Call for Proposals is to be launched in autumn 2009. It is planned to seek proposals for projects in oncology, diagnosis of infectious diseases, chronic inflammatory diseases and knowledge management. About the Innovative Medicines Initiative Launched in 2007, the Innovative Medicines Initiative was one of the first Joint Technology Initiatives (JTI) to be created. The total IMI budget for the period 2008-2013 is €2 billion (1 billion from the European Community and 1 billion from the industry). Created in 2007, the Innovative Medicines Initiative Joint Undertaking (IMI JU), representing both the European Community and the industry, implements IMI and is responsible for the launch of Calls for Proposals and the award of grants. To find out more about IMI: http://imi.europa.eu and http://www.imi-europe.org To find out more about Joint Technology Initiatives: http://cordis.europa.eu/fp7/jtis/ The Irish Pharmaceutical Healthcare Association and The European Federation of Pharmaceutical Industries and Associations


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

Copyright 2009